https://hdl.handle.net/20.500.11811/663 Wed, 15 Apr 2026 00:13:39 GMT 2026-04-15T00:13:39Z https://hdl.handle.net/20.500.11811/10818 Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy Kraft, Fabian; Hanl, Maria; Feller, Felix; Schäker-Hübner, Linda; Hansen, Finn Histone deacetylases (HDACs) play a key role in the control of transcription, cell prolifer- ation, and migration. FDA-approved histone deacetylase inhibitors (HDACi) demonstrate clinical efficacy in the treatment of different T-cell lymphomas and multiple myeloma. However, due to unselective inhibition, they display a wide range of adverse effects. One approach to avoiding off- target effects is the use of prodrugs enabling a controlled release of the inhibitor in the target tissue. Herein, we describe the synthesis and biological evaluation of HDACi prodrugs with photo-cleavable protecting groups masking the zinc-binding group of the established HDACi DDK137 (I) and VK1 (II). Initial decaging experiments confirmed that the photocaged HDACi pc-I could be deprotected to its parent inhibitor I. In HDAC inhibition assays, pc-I displayed only low inhibitory activity against HDAC1 and HDAC6. After irradiation with light, the inhibitory activity of pc-I strongly increased. Subsequent MTT viability assays, whole-cell HDAC inhibition assays, and immunoblot analysis confirmed the inactivity of pc-I at the cellular level. Upon irradiation, pc-I demonstrated pronounced HDAC inhibitory and antiproliferative activities which were comparable to the parent inhibitor I. Additionally, only phototreated pc-I was able to induce apoptosis in Annexin V/PI and caspase-Glo 3/7 assays, making pc-I a valuable tool for the development of light-activatable HDACi. Sat, 25 Feb 2023 00:00:00 GMT https://hdl.handle.net/20.500.11811/10818 2023-02-25T00:00:00Z